LTPA2022503I1 - - Google Patents
Info
- Publication number
- LTPA2022503I1 LTPA2022503I1 LTPA2022503C LTPA2022503C LTPA2022503I1 LT PA2022503 I1 LTPA2022503 I1 LT PA2022503I1 LT PA2022503 C LTPA2022503 C LT PA2022503C LT PA2022503 C LTPA2022503 C LT PA2022503C LT PA2022503 I1 LTPA2022503 I1 LT PA2022503I1
- Authority
- LT
- Lithuania
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82236206P | 2006-08-14 | 2006-08-14 | |
EP07840953.9A EP2059536B1 (en) | 2006-08-14 | 2007-08-14 | Optimized antibodies that target cd19 |
Publications (1)
Publication Number | Publication Date |
---|---|
LTPA2022503I1 true LTPA2022503I1 (lt) | 2022-04-11 |
Family
ID=39083071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTPA2022503C LTPA2022503I1 (lt) | 2006-08-14 | 2022-02-24 |
Country Status (20)
Country | Link |
---|---|
US (7) | US8524867B2 (lt) |
EP (2) | EP2383297B8 (lt) |
JP (4) | JP5825756B2 (lt) |
AU (1) | AU2007285976B2 (lt) |
CA (1) | CA2658557C (lt) |
DK (2) | DK2059536T3 (lt) |
ES (2) | ES2457072T3 (lt) |
FI (1) | FIC20220006I1 (lt) |
FR (1) | FR22C1007I2 (lt) |
HK (1) | HK1131168A1 (lt) |
HR (2) | HRP20130314T2 (lt) |
HU (1) | HUS2200007I1 (lt) |
LT (1) | LTPA2022503I1 (lt) |
ME (1) | ME01786B (lt) |
NL (1) | NL301163I2 (lt) |
PL (2) | PL2383297T3 (lt) |
PT (2) | PT2383297E (lt) |
RS (2) | RS52775B9 (lt) |
SI (2) | SI2383297T1 (lt) |
WO (1) | WO2008022152A2 (lt) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101463631B1 (ko) | 2006-03-31 | 2014-11-19 | 추가이 세이야쿠 가부시키가이샤 | 항체의 혈중 동태를 제어하는 방법 |
CA2658557C (en) * | 2006-08-14 | 2015-12-01 | Xencor, Inc. | Optimized antibodies that target cd19 |
WO2008150494A1 (en) * | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
RU2526512C2 (ru) | 2007-09-26 | 2014-08-20 | Чугаи Сейяку Кабусики Кайся | Модифицированная константная область антитела |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
US7968687B2 (en) | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
PL2708558T3 (pl) | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
CA2722466A1 (en) | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
AU2009256246B2 (en) | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2321422A4 (en) | 2008-07-08 | 2013-06-19 | Abbvie Inc | PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF |
PT2982696T (pt) * | 2008-11-07 | 2019-06-04 | Amgen Res Munich Gmbh | Tratamento da leucemia linfoblástica aguda |
ES2662929T3 (es) * | 2008-11-07 | 2018-04-10 | Amgen Research (Munich) Gmbh | Tratamiento de leucemia linfoblástica aguda pediátrica |
ES2527173T3 (es) | 2009-06-02 | 2015-01-21 | Regeneron Pharmaceuticals, Inc. | Células de fucosilación deficiente |
PE20121531A1 (es) | 2009-10-15 | 2012-12-22 | Abbott Lab | Inmunoglobulinas con dominio variable dual |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
CN103080130B (zh) | 2010-05-27 | 2016-08-17 | 默沙东公司 | 制备具有改进特性的抗体的方法 |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
EP2409989A1 (en) * | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Method to improve glycosylation profile for antibody |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
NZ607480A (en) | 2010-08-03 | 2014-10-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
BR112013004581A2 (pt) | 2010-08-26 | 2017-06-27 | Abbvie Inc | imunoglobulinas de domínio variável dual e seus usos |
EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
SG192945A1 (en) | 2011-02-25 | 2013-09-30 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc antibody |
CN109517059B (zh) * | 2011-06-30 | 2023-03-28 | 中外制药株式会社 | 异源二聚化多肽 |
LT2744515T (lt) * | 2011-08-16 | 2022-04-25 | Morphosys Ag | Kombinuota terapija su anti-cd19 antikūnu ir azoto garstyčiomis |
ES2909720T3 (es) | 2011-08-16 | 2022-05-10 | Morphosys Ag | Terapia de combinación con un anticuerpo anti-CD19 y un análogo de purina |
EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
SG11201401101XA (en) | 2011-09-30 | 2014-08-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule for promoting loss of antigens |
BR112014013081A2 (pt) | 2011-11-30 | 2020-10-20 | Chugai Seiyaku Kabushiki Kaisha | veículo contendo fármaco em célula para formação de um complexo imune |
JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
CA2865158C (en) | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
KR20140148411A (ko) * | 2012-03-12 | 2014-12-31 | 메디뮨 엘엘씨 | 항-cd19 항체를 이용한 다발성 경화증의 치료 |
EP2844347A4 (en) * | 2012-05-01 | 2016-03-30 | Philadelphia Children Hospital | COMPOSITIONS AND METHODS FOR TREATING MALIGNANT B-LYMPHOID TUMORS |
KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 t 세포의 조작 방법 |
WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
EP2889376A4 (en) | 2012-08-24 | 2016-11-02 | Chugai Pharmaceutical Co Ltd | ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE |
KR102273985B1 (ko) | 2012-08-24 | 2021-07-06 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc영역 개변체 |
ES2703151T3 (es) | 2012-10-12 | 2019-03-07 | Adc Therapeutics Sa | Conjugados de anticuerpos de pirrolobenzodiazepinas |
ME03486B (me) | 2012-10-12 | 2020-01-20 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
AR093311A1 (es) | 2012-11-01 | 2015-05-27 | Abbvie Inc | Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4) |
CA2890483A1 (en) | 2012-11-09 | 2014-05-15 | Robert ARCH | Platelet-derived growth factor b specific antibodies and compositions and uses thereof |
CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
AU2014248636B2 (en) | 2013-03-12 | 2017-03-30 | Decimmune Therapeutics, Inc. | Humanized anti-N2 antibodies |
US20160031887A1 (en) | 2013-03-13 | 2016-02-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
MX2015013166A (es) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. |
US9561291B2 (en) * | 2013-03-15 | 2017-02-07 | Imre Kovesdi | Methods of targeting T-cells to tumors |
CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
PT2997141T (pt) * | 2013-05-13 | 2022-11-23 | Cellectis | Recetor de antigénio quimérico específico para cd19 e utilizações do mesmo |
US11077144B2 (en) | 2013-05-13 | 2021-08-03 | Cellectis | CD19 specific chimeric antigen receptor and uses thereof |
EP3050896B1 (en) | 2013-09-27 | 2021-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
SG11201602671WA (en) | 2013-11-13 | 2016-05-30 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
TW201524998A (zh) * | 2013-12-31 | 2015-07-01 | Dev Center Biotechnology | 抗vegf抗體及其用途 |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
IL249533A0 (en) * | 2014-06-16 | 2017-02-28 | Xencor Inc | Treatment of chronic lymphocytic leukemia |
WO2015195498A1 (en) * | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
USD791796S1 (en) * | 2014-09-11 | 2017-07-11 | Express Scripts, Inc. | Display screen with a graphical user interface |
USD791797S1 (en) * | 2014-09-11 | 2017-07-11 | Express Scripts, Inc. | Display screen with a graphical user interface |
USD801353S1 (en) * | 2014-09-11 | 2017-10-31 | Express Scripts, Inc. | Display screen with a graphical user interface |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
RS61870B1 (sr) | 2014-11-14 | 2021-06-30 | Hoffmann La Roche | Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
CN107108726A (zh) | 2014-12-19 | 2017-08-29 | 中外制药株式会社 | 抗‑肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法 |
EP3816179A3 (en) | 2015-02-05 | 2021-08-04 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
EP3973980A1 (en) * | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
US10617691B2 (en) | 2015-05-26 | 2020-04-14 | Morphosys Ag | Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
EP3325010B1 (en) | 2015-07-23 | 2023-06-21 | The Regents of The University of California | Antibodies to coagulation factor xia and uses thereof |
HUE056408T2 (hu) | 2015-08-21 | 2022-02-28 | Morphosys Ag | Kombinációk és alkalmazásaik |
MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
MX2018003827A (es) * | 2015-10-02 | 2018-06-22 | Hoffmann La Roche | Anticuerpos anti-cd19 humano con alta afinidad. |
CN109071648B (zh) | 2015-10-23 | 2022-07-19 | 辉瑞有限公司 | 抗il-2抗体及其组合物和用途 |
WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
US20190195879A1 (en) | 2016-05-30 | 2019-06-27 | Morphosys Ag | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
EP3468997B1 (en) | 2016-06-08 | 2023-09-13 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
KR102533875B1 (ko) | 2016-06-27 | 2023-05-18 | 모르포시스 아게 | 항-cd19 항체 제제 |
TW202300168A (zh) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
ES2871574T3 (es) | 2016-10-28 | 2021-10-29 | Morphosys Ag | Combinación de anticuerpo anti CD19 con un inhibidor de BCL-2 y usos de la misma |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
UA125198C2 (uk) | 2017-02-08 | 2022-01-26 | Ейдісі Терапьютікс Са | Кон'югати піролобензодіазепін-антитіло |
ES2926144T3 (es) | 2017-04-18 | 2022-10-24 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
LT3630177T (lt) | 2017-05-31 | 2023-10-25 | Morphosys Ag | Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu |
JP7279011B2 (ja) | 2017-07-10 | 2023-05-22 | インターナショナル-ドラッグ-ディベロップメント-バイオテック | 抗cd20抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗cd19抗体を用いるb細胞悪性の治療 |
HRP20220311T1 (hr) | 2017-08-18 | 2022-05-13 | Medimmune Limited | Konjugati pirolobenzodiazepina |
BR112020005402A2 (pt) * | 2017-09-21 | 2020-09-29 | WuXi Biologics Ireland Limited | anticorpos, sequências de polinucleotídeo e de ácido nucleico, vetores, célula hospedeira, métodos de expressar o anticorpo e de modulação conjugado, composição farmacêutica, métodos para tratar uma doença, para detectar, para diagnosticar e para estimular uma resposta imune, método in vivo ou in vitro, uso, receptor de antígeno quimérico e célula t |
MX2020006297A (es) | 2017-12-15 | 2020-12-07 | Aleta Biotherapeutics Inc | Variantes de cd19. |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
MX2020009296A (es) | 2018-03-15 | 2020-11-13 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso. |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP3796942A1 (en) | 2018-05-23 | 2021-03-31 | ADC Therapeutics SA | Molecular adjuvant |
US11555071B2 (en) | 2018-06-03 | 2023-01-17 | Lamkap Bio Beta Ltd. | Bispecific antibodies against CEACAM5 and CD47 |
CN113272327A (zh) | 2018-12-30 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 抗兔cd19抗体及其使用方法 |
JP2022532519A (ja) | 2019-05-03 | 2022-07-15 | モルフォシス・アーゲー | 限られた数のnk細胞を有する患者における抗cd19療法 |
US20220347298A1 (en) | 2019-10-04 | 2022-11-03 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
WO2021084064A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Sequential anti-cd19 therapy |
MX2022005031A (es) | 2019-10-31 | 2022-07-27 | Morphosys Ag | Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas. |
IL292213A (en) | 2019-10-31 | 2022-06-01 | Morphosys Ag | Combination anti-tumor therapy including anti-cd19 antibody and gamma delta t cells |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
IL293310A (en) | 2019-12-18 | 2022-07-01 | Hoffmann La Roche | Bispecific anti-ccl2 antibodies |
EP3869302A1 (en) | 2020-02-18 | 2021-08-25 | Bayerische Motoren Werke Aktiengesellschaft | Vehicle, apparatus and method to reduce the occurence of motion sickness |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
AU2021298106A1 (en) | 2020-06-22 | 2023-01-19 | Gilead Sciences, Inc. | Anti-tumor combination therapy comprising anti-CD19 antibody and polypeptides blocking the SIRPalpha-CD47 innate immune checkpoint |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
MX2023003997A (es) | 2020-10-06 | 2023-06-15 | Xencor Inc | Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les). |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
WO2022115762A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
EP4255480A2 (en) | 2020-12-04 | 2023-10-11 | MorphoSys AG | Anti-cd19 combination therapy |
KR20230121772A (ko) | 2020-12-18 | 2023-08-21 | 람카프 바이오 베타 엘티디. | Ceacam5 및 cd47에 대한 이중특이적 항체 |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
EP4326288A1 (en) | 2021-04-21 | 2024-02-28 | Indapta Therapeutics, Inc. | Methods of treatment and dosing of natural killer cell compositions |
CN117500829A (zh) | 2021-06-18 | 2024-02-02 | 豪夫迈·罗氏有限公司 | 双特异性抗ccl2抗体 |
WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
US20230357392A1 (en) | 2021-12-22 | 2023-11-09 | Morphosys Ag | Treatment Paradigm for an Anti-CD19 Antibody Therapy |
WO2023178285A1 (en) | 2022-03-17 | 2023-09-21 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2023201339A1 (en) | 2022-04-15 | 2023-10-19 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
Family Cites Families (211)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US618965A (en) * | 1899-02-07 | Filter | ||
US2228904A (en) | 1939-05-10 | 1941-01-14 | Bjorkman Hugo Leonard | Wrench |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
JP2713410B2 (ja) | 1986-05-29 | 1998-02-16 | イレクサス ピーティワイ リミテッド | 免疫グロブリンに対するFcレセプター |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US5681566A (en) | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20030229208A1 (en) | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規dnaならびにそれを含有する発現プラスミド |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
PT95809A (pt) | 1989-11-07 | 1991-09-13 | Bristol Myers Squibb Co | Processo para a preparacao de imunoglobulinas oligomericas, nomeadamente anticorpos monoclonais oligomericos |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1991013974A1 (en) | 1990-03-14 | 1991-09-19 | The Biomembrane Institute | Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders |
WO1991019515A1 (en) | 1990-06-21 | 1991-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity |
US5198342A (en) | 1990-07-05 | 1993-03-30 | Immunex Corporation | DNA encoding IgA Fc receptors |
JPH06500780A (ja) | 1990-08-31 | 1994-01-27 | ブリストル―マイアーズ スクイブ カンパニー | ホモ接合免疫グロブリン |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5623053A (en) | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5686072A (en) * | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
ATE240395T1 (de) | 1994-03-29 | 2003-05-15 | Celltech Therapeutics Ltd | Antikörper gegen e-selektin |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
WO1996003397A1 (en) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
EP0805628B1 (en) | 1995-01-17 | 2003-05-02 | Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
US6444789B1 (en) | 1995-05-03 | 2002-09-03 | Applied Research Systems Ars Holding N.V. | CD16-II variants |
EP0835134A1 (en) | 1995-05-17 | 1998-04-15 | Regents Of The University Of Minnesota | Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6365161B1 (en) | 1995-06-07 | 2002-04-02 | Medarex, Inc. | Therapeutic compounds comprised of anti-FC receptor binding agents |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
EP0888125B1 (en) | 1996-03-20 | 2004-05-26 | Immunomedics, Inc. | GLYCOSYLATED IgG ANTIBODIES |
PT892789E (pt) | 1996-04-12 | 2002-07-31 | Warner Lambert Co | Inibidores irreversiveis de quinases de tirosina |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
JP2000516452A (ja) | 1996-07-16 | 2000-12-12 | プリュックテュン,アンドレアス | 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント |
DE69738522T2 (de) | 1996-08-02 | 2009-04-02 | Bristol-Myers Squibb Co. | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
WO1998031806A2 (en) | 1997-01-21 | 1998-07-23 | Human Genome Sciences, Inc. | Fc RECEPTORS AND POLYPEPTIDES |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
WO1998047089A1 (en) | 1997-04-11 | 1998-10-22 | California Institute Of Technology | Apparatus and method for automated protein design |
EP1255209A3 (en) | 1997-04-11 | 2009-02-11 | California Institute Of Technology | Apparatus and method for automated protein design |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20040191256A1 (en) | 1997-06-24 | 2004-09-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
PT1071752E (pt) | 1998-04-21 | 2003-11-28 | Micromet Ag | Polipeptidos especificos para cd19xcd3 e suas utilizacoes |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
WO1999056777A1 (en) | 1998-05-06 | 1999-11-11 | Temple University - Of The Commonwealth System Of Higher Education | REVERSAL OF PROINFLAMMATORY RESPONSE BY LIGATING THE MACROPHAGE FcηRI RECEPTOR |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6306926B1 (en) | 1998-10-07 | 2001-10-23 | 3M Innovative Properties Company | Radiopaque cationically polymerizable compositions comprising a radiopacifying filler, and method for polymerizing same |
US20020048772A1 (en) | 2000-02-10 | 2002-04-25 | Dahiyat Bassil I. | Protein design automation for protein libraries |
US20030049654A1 (en) | 1998-10-16 | 2003-03-13 | Xencor | Protein design automation for protein libraries |
US6403312B1 (en) | 1998-10-16 | 2002-06-11 | Xencor | Protein design automatic for protein libraries |
CA2347214A1 (en) | 1998-10-16 | 2000-04-27 | Klaus M. Fiebig | Protein design automation for protein libraries |
US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP2003512019A (ja) | 1999-01-15 | 2003-04-02 | ジェネンテック・インコーポレーテッド | 変化したエフェクター機能を有するポリペプチド変異体 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
EP1194167B1 (en) | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
US6638515B2 (en) | 1999-09-07 | 2003-10-28 | Walter Schubert | Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
ES2586850T3 (es) | 1999-11-29 | 2016-10-19 | The Trustees Of Columbia University In The City Of New York | Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma |
DE19958134C2 (de) | 1999-12-02 | 2003-05-15 | Koenig & Bauer Ag | Saugwalze |
CA2399561A1 (en) | 2000-02-03 | 2001-08-09 | Lennart Hammarstrom | Ruminant mhc class i-like fc receptors |
JP2003521933A (ja) | 2000-02-10 | 2003-07-22 | ゼンコー | タンパク質ライブラリーに関するタンパク質設計オートメーション |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
US6358733B1 (en) | 2000-05-19 | 2002-03-19 | Apolife, Inc. | Expression of heterologous multi-domain proteins in yeast |
JP2003535907A (ja) | 2000-06-22 | 2003-12-02 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法 |
AU2001291175A1 (en) | 2000-09-21 | 2002-04-02 | Md Online Inc. | Medical image processing systems |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
US7235643B2 (en) | 2000-11-07 | 2007-06-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with high affinity |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン,エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
DE60135498D1 (de) | 2000-12-14 | 2008-10-02 | Genentech Inc | Produktion von ganzen Antikörpern in prokaryontischen Zellen |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1358337A1 (en) | 2001-01-30 | 2003-11-05 | Degussa AG | Nucleotide sequences which code for the otsa gene of c. glutamicum |
CN100574803C (zh) | 2001-01-31 | 2009-12-30 | 拜奥根Idec公司 | 免疫调节抗体在治疗肿瘤性疾病中的用途 |
US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20040136908A1 (en) | 2001-04-09 | 2004-07-15 | Olson William C. | Anti-cd19 immunotoxins |
CN1463270A (zh) | 2001-05-31 | 2003-12-24 | 梅达莱克斯公司 | 细胞毒素、其有用的前体药物、连接基团和稳定剂 |
GB0118662D0 (en) | 2001-07-31 | 2001-09-19 | Univ Southampton | Binding agents |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
US7255858B2 (en) | 2001-08-10 | 2007-08-14 | University Of Virginia Patent Foundation | Enhancing the efficacy of immunotherapies by supplementing with complement |
EP1432980A4 (en) | 2001-08-10 | 2006-04-12 | Xencor Inc | AUTOMATED PROTEIN CONSTRUCTION FOR PROTEIN LIBRARIES |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
DE60127143T2 (de) | 2001-11-14 | 2007-11-15 | Affimed Therapeutics Ag | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung |
US6911321B2 (en) | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
AU2003216250A1 (en) | 2002-02-11 | 2003-09-04 | Genentech, Inc. | Antibody variants with faster antigen association rates |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
US20080260731A1 (en) | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
AU2002316574B2 (en) | 2002-03-15 | 2008-05-01 | Brandeis University | Central airway administration for systemic delivery of therapeutics |
EP1490085A2 (en) | 2002-03-25 | 2004-12-29 | Uab Research Foundation | Fc receptor homolog, reagents, and uses thereof |
WO2003085119A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia |
EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
JP2006513139A (ja) | 2002-07-03 | 2006-04-20 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 治療薬の全身性送達のための中央部気道投与 |
US20060062727A1 (en) | 2002-07-09 | 2006-03-23 | Philips Heidi S | Compositions and methods for the diagnosis and treatment of tumor |
WO2004016750A2 (en) | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
AU2003270369A1 (en) | 2002-09-05 | 2004-03-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen |
US20060153839A1 (en) | 2002-09-16 | 2006-07-13 | Elusys Therapeutics, Inc. | Production of bispecific molecules using polyethylene glycol linkers |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
PL212899B1 (pl) | 2002-12-16 | 2012-12-31 | Genentech Inc | Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
LT2335725T (lt) | 2003-04-04 | 2017-01-25 | Genentech, Inc. | Didelės koncentracijos antikūno ir baltymo kompozicijos |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
KR101441358B1 (ko) | 2003-05-14 | 2014-09-24 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
AU2004257142A1 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
DK1641483T3 (da) | 2003-06-12 | 2008-06-02 | Lilly Co Eli | Fusionsproteiner |
NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
EP1644416A4 (en) | 2003-06-30 | 2007-08-29 | Centocor Inc | ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
EP2292264A3 (en) | 2003-07-24 | 2012-12-19 | Innate Pharma | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
NZ580688A (en) | 2003-07-26 | 2012-03-30 | Biogen Idec Inc | Method of designing altered antibodies having improved antigen-binding affinity |
CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
WO2005013090A2 (en) | 2003-08-01 | 2005-02-10 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
JP2007503206A (ja) | 2003-08-22 | 2007-02-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法 |
AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
CA2579635A1 (en) | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
CA2545539A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
ES2341252T3 (es) | 2003-11-28 | 2010-06-17 | Micromet Ag | Composiciones que comprenden polipeptidos. |
EA009746B1 (ru) | 2004-01-12 | 2008-04-28 | Эпплайд Молекьюлар Эволюшн, Инк. | ВАРИАНТЫ УЧАСТКА Fc |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
KR100545720B1 (ko) | 2004-05-31 | 2006-01-24 | 메덱스젠 주식회사 | 당화된 면역글로불린 및 이를 포함하는 면역접합체 |
BRPI0513601A (pt) | 2004-07-23 | 2008-05-13 | Genentech Inc | métodos de produção de cristais de anticorpo ou seu fragmento, composições, formulação, cristal de anticorpo ou seu fragmento, método de tratamento e métodos de produção de cristais e de gel de proteìna de anticorpo ou seu fragmento |
WO2006047350A2 (en) * | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
CA2597924C (en) | 2005-02-15 | 2018-10-02 | Duke University | Anti-cd19 antibodies and uses in oncology |
CA2607281C (en) | 2005-05-05 | 2023-10-03 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
EP1904101A4 (en) * | 2005-06-08 | 2011-06-15 | Univ Duke | ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION |
WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
RU2008129080A (ru) | 2005-12-16 | 2010-01-27 | Микромет Аг (De) | Средства и способы лечения опухолевых заболеваний |
CA2635623C (en) | 2005-12-30 | 2015-02-17 | Michael Super | Anti-cd19 antibodies with reduced immunogenicity |
US20070166306A1 (en) | 2006-01-17 | 2007-07-19 | Fey Georg H M | Anti-CD19 antibody composition and method |
US20070178103A1 (en) | 2006-01-30 | 2007-08-02 | Fey Georg H | CD19-specific immunotoxin and treatment method |
CA2658557C (en) | 2006-08-14 | 2015-12-01 | Xencor, Inc. | Optimized antibodies that target cd19 |
PL2066349T3 (pl) | 2006-09-08 | 2012-09-28 | Medimmune Llc | Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych |
US20080267977A1 (en) | 2007-04-26 | 2008-10-30 | Friedrich-Alexander University Of Erlangen-Nuremberg | Combined immunological agent and sensitizing agent for the treatment of cancer |
WO2008150494A1 (en) * | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
US9098105B2 (en) | 2012-08-24 | 2015-08-04 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Dynamic Y-buffer size adjustment for retained sector reprocessing |
US9679104B2 (en) | 2013-01-17 | 2017-06-13 | Edico Genome, Corp. | Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform |
US9703321B2 (en) | 2013-07-09 | 2017-07-11 | I-Blades, Inc. | Snap on wearable module |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2007
- 2007-08-14 CA CA2658557A patent/CA2658557C/en active Active
- 2007-08-14 DK DK07840953.9T patent/DK2059536T3/da active
- 2007-08-14 DK DK11173336.6T patent/DK2383297T5/da active
- 2007-08-14 RS RS20130134A patent/RS52775B9/sr unknown
- 2007-08-14 WO PCT/US2007/075932 patent/WO2008022152A2/en active Application Filing
- 2007-08-14 RS RS20140165A patent/RS53263B/en unknown
- 2007-08-14 EP EP11173336.6A patent/EP2383297B8/en active Active
- 2007-08-14 PL PL11173336T patent/PL2383297T3/pl unknown
- 2007-08-14 US US12/377,251 patent/US8524867B2/en active Active
- 2007-08-14 PL PL07840953T patent/PL2059536T3/pl unknown
- 2007-08-14 ME MEP-2014-35A patent/ME01786B/me unknown
- 2007-08-14 ES ES07840953.9T patent/ES2457072T3/es active Active
- 2007-08-14 PT PT111733366T patent/PT2383297E/pt unknown
- 2007-08-14 EP EP07840953.9A patent/EP2059536B1/en active Active
- 2007-08-14 AU AU2007285976A patent/AU2007285976B2/en active Active
- 2007-08-14 PT PT78409539T patent/PT2059536E/pt unknown
- 2007-08-14 SI SI200731159T patent/SI2383297T1/sl unknown
- 2007-08-14 SI SI200731437T patent/SI2059536T1/sl unknown
- 2007-08-14 ES ES11173336T patent/ES2402591T3/es active Active
- 2007-08-14 JP JP2009524772A patent/JP5825756B2/ja active Active
-
2009
- 2009-11-20 HK HK09110913.4A patent/HK1131168A1/xx unknown
-
2011
- 2011-05-06 JP JP2011103488A patent/JP5645747B2/ja active Active
- 2011-08-30 US US13/221,811 patent/US20120082664A1/en not_active Abandoned
-
2013
- 2013-04-05 HR HRP20130314TT patent/HRP20130314T2/hr unknown
- 2013-06-04 JP JP2013118273A patent/JP2013177443A/ja active Pending
- 2013-08-05 US US13/959,587 patent/US9803020B2/en active Active
- 2013-09-10 US US14/023,305 patent/US20140112916A1/en not_active Abandoned
-
2014
- 2014-04-07 HR HRP20140331TT patent/HRP20140331T1/hr unknown
-
2015
- 2015-09-11 JP JP2015179854A patent/JP2015221839A/ja active Pending
-
2017
- 2017-09-22 US US15/712,918 patent/US10626182B2/en active Active
-
2020
- 2020-04-01 US US16/837,678 patent/US11618788B2/en active Active
-
2022
- 2022-02-18 FR FR22C1007C patent/FR22C1007I2/fr active Active
- 2022-02-18 HU HUS2200007C patent/HUS2200007I1/hu unknown
- 2022-02-21 FI FIC20220006C patent/FIC20220006I1/fi unknown
- 2022-02-22 NL NL301163C patent/NL301163I2/nl unknown
- 2022-02-24 LT LTPA2022503C patent/LTPA2022503I1/lt unknown
-
2023
- 2023-02-21 US US18/172,196 patent/US20230340144A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2022503I1 (lt) | ||
BRPI0720064A2 (lt) | ||
BRMU8603216U8 (lt) | ||
BRPI0715824A8 (lt) | ||
BRPI0713487A2 (lt) | ||
BR122016023444A2 (lt) | ||
BRPI0708307B8 (lt) | ||
CH2121272H1 (lt) | ||
BY9789C1 (lt) | ||
CN300725943S (zh) | 童装(3876) | |
CN300725939S (zh) | 童装裤子(3856) | |
CN300729945S (zh) | 插头(美规) | |
CN300729937S (zh) | 四芯硅橡胶冷缩指套 | |
CN300729045S (zh) | 杯子 | |
CN300728537S (zh) | 拖鞋(3356) | |
CN300730076S (zh) | 液晶电视(hac系列) | |
CN300728150S (zh) | 电动执行器(2型) | |
CN300727795S (zh) | 带有录像重放机的摄像机 | |
CN300730319S (zh) | 插片(11) | |
CN300732183S (zh) | 包装袋(五五五鸡鲜味火锅汤料) | |
CN300727791S (zh) | 摄像头(acm-378) | |
CN300727061S (zh) | 铅笔包装袋(171) | |
CN300725929S (zh) | 童装(3811) | |
CN300726155S (zh) | 印花面料(快活丛林一系列) | |
CN300731023S (zh) | 浴帽(鸭子造型) |